Optimizing the Use of Pneumococcal Conjugate Vaccine Globally
- 4 September 2013
- journal article
- editorial
- Published by American Medical Association (AMA)
- Vol. 310 (9) , 911-913
Abstract
Pneumococcal conjugate vaccine (PCV) was first licensed in 2000 as a 7-valent product and is now available as 10- and 13-valent products (PCV10 and PCV13). As recommended by the World Health Organization,1 PCVs are now in routine use in more than 95 of 194 countries globally, including use in 27 GAVI Alliance–eligible countries and approval for use in an additional 24 such countries.2 Financial investments by individual countries and the international community, through the GAVI Alliance, are ensuring the sustainable availability of PCV in the places where it is most needed—the poorest countries where children have a substantial risk of serious illness and death from pneumococcal disease. In 2008, more than 500 000 children under 5 years died from pneumococcal disease.3 This mortality and the larger burden of serious morbidity, mostly from pneumococcal pneumonia,4 is the focus of PCV programs.Keywords
This publication has 4 references indexed in Scilit:
- Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: Systematic review and meta-analysisVaccine, 2011
- Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimatesThe Lancet, 2009
- Immunogenicity and Boosting After a Reduced Number of Doses of a Pneumococcal Conjugate Vaccine in Infants and ToddlersThe Pediatric Infectious Disease Journal, 2006
- Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy studyThe Lancet, 2006